Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug.
El Alaoui
Abdessamad
A
UMR 176 CNRS, Institut Curie, Centre de Recherche, 26 rue d'Ulm 75248 Paris Cedex 05, France.
Schmidt
Frédéric
F
Amessou
Mohamed
M
Sarr
Marianne
M
Decaudin
Didier
D
Florent
Jean-Claude
JC
Johannes
Ludger
L
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000494:pharmacology*; D001710:Biotin / Q000494:pharmacology; D016466:CHO Cells; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D006224:Cricetinae; D003412:Cricetulus; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology*; D004797:Enzyme-Linked Immunosorbent Assay; D019073:HT29 Cells; D006801:Humans; D000077146:Irinotecan; D011355:Prodrugs / Q000008:administration & dosage* / Q000494:pharmacology*; D022621:Shiga Toxin / Q000494:pharmacology*; D022603:Shiga Toxins / Q000494:pharmacology; D059005:Topoisomerase II Inhibitors; D014281:Trihexosylceramides / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D011355:Prodrugs; D022603:Shiga Toxins; D059005:Topoisomerase II Inhibitors; D014281:Trihexosylceramides; C077239:stxB toxin; D001710:Biotin; C018549:globotriaosylceramide; D022621:Shiga Toxin; D000077146:Irinotecan; D002166:Camptothecin